Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection

References

• Afzal N, Ganguly PK, Dhalla KS, Pierce GN, Singal PK, Dhalla NS. (1988). Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37:936–942.
   PubMedGoogle Scholar
• Andersson DE, Röjdmark S. (1981). Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 210:27–33.
   PubMedGoogle Scholar
• Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani R, Zenere MB, Monauni T, Muggeo M.. (2000). Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57–63.
   PubMed Web of Science ®Google Scholar
• Bradford MM.. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
   PubMed Web of Science ®Google Scholar
• Choi JS, Burm JP. (2005). Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. Arch Pharm Res 28:483–487.
   PubMed Web of Science ®Google Scholar
• Fleckenstein A. (1977). Specific pharmacology of calcium in myocardium, cardiac pacemarkers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149–166.
   PubMed Web of Science ®Google Scholar
• Gould BA, Mann S, Kieso H, Subramanian VB, Raftery EB. (1982). The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65:22–27.
   PubMed Web of Science ®Google Scholar
• Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, Zhang L, Liu H, Liu X, Liu X, Xie L, Wang G. (2010). Opposite Effect of Diabetes Mellitus Induced by Streptozotocin on Oral and Intravenous Pharmacokinetics of Verapamil in Rats. Drug Metab Dispos (In Press).
   Google Scholar
• Irizar A, Ioannides C. (1998). Marked inhibition of hepatic cytochrome P450 activity in cholesterol-induced atherosclerosis in rabbits. Toxicology 126:179–193.
   PubMed Web of Science ®Google Scholar
• Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, Wakusawa S. (2008). Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim Biophys Acta 1782:355–360.
   PubMed Web of Science ®Google Scholar
• Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114–123.
   PubMed Web of Science ®Google Scholar
• Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. (1993). Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332–337.
   PubMed Web of Science ®Google Scholar
• Kudo T, Shimada T, Ushiki T, Ohi K, Ikarashi N, Ochiai W, Sugiyama K. (2010). Differences in the pharmacokinetics of Cyp3a substrates in TSOD and Streptozotocin-induced diabetic mice. Xenobiotica 39:889–902.
   Google Scholar
• Kudo T, Toda T, Ushiki T, Ohi K, Ikarashi N, Ochiai W, Sugiyama K. (2009). Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Xenobiotica 40:282–290.
   Google Scholar
• Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. (1998). Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 12:553–558.
   PubMed Web of Science ®Google Scholar
• Marques MP, Coelho EB, Dos Santos NA, Geleilete TJ, Lanchote VL. (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58:607–614.
   PubMed Web of Science ®Google Scholar
• Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. (2000). Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182–190.
   PubMed Web of Science ®Google Scholar
• Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. (2005). A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28:736–744.
   PubMed Web of Science ®Google Scholar
• Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. (2000). A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metab Clin Exp 49:1390–1394.
   PubMed Web of Science ®Google Scholar
• Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda K. (1993). Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 46:621–627.
   PubMed Web of Science ®Google Scholar
• Shimojo N. (1994). Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int J Biochem 26:1261–1268.
   PubMedGoogle Scholar
• Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. (2005). Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313–320.
   PubMed Web of Science ®Google Scholar
• Stewart CC, Strother A. (1999). Glucose consumption by rats decreases cytochrome P450 enzyme activity by altering hepatic lipids. Life Sci 64:2163–2172.
   PubMedGoogle Scholar
• Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. (2002). Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90:155–160.
   PubMedGoogle Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430.
   PubMed Web of Science ®Google Scholar
• Ueyama J, Wang D, Kondo T, Saito I, Takagi K, Takagi K, Kamijima M, Nakajima T, Miyamoto K, Wakusawa S, Hasegawa T. (2007). Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett 170:229–237.
   PubMed Web of Science ®Google Scholar
• Ueyama J, Kamijima M, Asai K, Mochizuki A, Wang D, Kondo T, Suzuki T, Takagi K, Takagi K, Kanazawa H, Miyamoto K, Wakusawa S, Hasegawa T. (2008). Effect of the organophosphorus pesticide diazinon on glucose tolerance in type 2 diabetic rats. Toxicol Lett 182:42–47.
   PubMed Web of Science ®Google Scholar
• Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. (2007). Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 40:964–968.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77–85.
   PubMed Web of Science ®Google Scholar
• Watson AM, Poloyac SM, Howard G, Blouin RA. (1999). Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 27:695–700.
   PubMed Web of Science ®Google Scholar
• Xie SS, Hu N, Jing XY, Liu XD, Xie L, Wang GJ, Liu CH. (2010). Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. J Pharm Pharmacol 62:440–447.
   PubMedGoogle Scholar